AZD2171 in Treating Patients with Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
February 17, 2006

Alternative Title

Phase II Study of AZD2171 in Patients With Unresectable Malignant Pleural Mesothelioma

Basic Trial Information

Trial Description

Purpose:

AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

This phase II trial is study how well AZD2171 works in treating patients with malignant pleural mesothelioma that cannot be removed by surgery.

Eligibility:

Eligibility criteria include the following:

    · At least 18 years old
    · Measurable disease
    · Must have received chemotherapy that included drugs such as cisplatin or carboplatin
    · No CNS metastases
    · No more than one previous chemotherapy regimen
    · At least 4 weeks since chemotherapy or surgery
    · At least 3 weeks since radiation therapy

Final eligibility for a clinical trial is determined by the health professionals conducting the trial. For more details about the eligibility requirements for this trial and the treatment or intervention, refer to the Health Professional version of the trial summary.

Treatment/Intervention:

Patients will receive AZD2171 by mouth once a day. Treatment may continue for as long as benefit is shown.

After finishing treatment, patients will be evaluated periodically for up to 5 years.

Important:

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations:

Southwest Oncology Group

Linda Garland, MD, Protocol chair
     Ph: 520-626-3434; 800-622-2673
     Email: lgarland@azcc.arizona.edu

Antoinette Wozniak, MD, Protocol co-chair
     Ph: 313-576-8752; 800-527-6266
     Email: wozniakt@karmanos.org

Trial Sites and Contacts:

U.S.A.

North Carolina

    Goldsboro

    Wayne Memorial Hospital, Incorporated
    James Atkins, MD
    Ph: 919-580-0000

     Wayne Radiation Oncology
    James Atkins, MD
    Ph: 919-580-0000

    Wilson

    Wilson Medical Center
    Clinical Trials Office - Wilson Medical Center
    Ph: 252-399-7491

Related Information

PDQ® clinical trial SWOG-S9925 - http://www.nci.nih.gov/search/ViewClinicalTrials.aspx?cdrid=78624&version=patient

***Source: http://www.cancer.gov/clinicaltrials***